Tradestie Institutional Equity Comparison Engine
ICCC vs IRIX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ICCC Overall Edge
ICCC Captures Institutional Edge (2โ0 Pillars ยท 8โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, ICCC trades at N/M Forward P/E with 15.2% operating margin (+11.5% YoY revenue) versus IRIX at N/M Forward P/E and -5.4% operating margin (-7.4% YoY). In options structure, ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IRIX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ICCC N/M vs IRIX N/M Fwd P/E
Growth & Margin Winner
ICCC
Op Margin 15.2% vs -5.4% ยท YoY +11.5% vs -7.4%
Momentum & Technical Winner
ICCC
1Y +88.8% vs -22.5% ยท 52W Pos 91% vs 8%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ICCC
NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap
$97.7M
1M Return
+6.23%
1Y Return
+88.76%
Forward P/E
N/M
Unified AI Score
43.8 / 100
HOLD
Tech 15.0
Fund 48.0
Flow 50.0
Mom 50.0
IRIX
NASDAQ
Iridex Corp
Electromedical & Electrotherapeutic Apparatus
$0.69
-0.32% 1D
Market Cap
$12.1M
1M Return
-15.57%
1Y Return
-22.49%
Forward P/E
N/M
Unified AI Score
51.8 / 100
HOLD
Tech 52.0
Fund 65.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ICCC +88.76%
IRIX -22.49%
Spread: +111.25 pp (ICCC Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ICCC Revenue | IRIX Revenue | ICCC Op. Margin | IRIX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $10M | $40M | -7.0% | -20.7% | ICCC |
| FY2020 | $20M | N/A | -9.0% | N/A | ICCC |
| FY2021 | $20M | $40M | 1.3% | -18.1% | ICCC |
| FY2022 | $20M | $60M | -12.4% | -13.2% | ICCC |
| FY2023 | $20M | $50M | -32.9% | -19.3% | IRIX |
| FY2024 | $30M | $50M | -6.2% | -17.1% | ICCC |
| FY2025 | $30M | N/A | 6.0% | N/A | ICCC |
| FY2026 | N/A | $50M | N/A | -4.9% | IRIX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ICCC | IRIX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $97.7M | $12.1M | Larger Scale | ICCC |
| Trailing P/E Ratio Valuation | 56.6x | N/M | Lower Multiple | ICCC |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +11.5% | -7.4% | Higher Growth | ICCC |
| Operating Margin (TTM) Profitability | 15.2% | -5.4% | Higher Margin | ICCC |
| Net Profit Margin Profitability | 2.6% | -6.9% | Higher Margin | ICCC |
| Return on Equity (ROE) Capital Efficiency | 2.6% | -73.2% | Higher ROE | ICCC |
| 52-Week Range Position Momentum | 91% ($5โ$12) | 8% ($1โ$2) | Stronger Trend | ICCC |
| Beta / 30D Volatility Risk Regime | 0.24ฮฒ ยท 46% Vol | 0.66ฮฒ ยท 58% Vol | Lower Realized Risk | ICCC |
| Unified Institutional Score Composite Signal | 43.8 / 100 (HOLD) | 51.8 / 100 (HOLD) | Higher Composite | IRIX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ICCC vs IRIX Buy Guide
ICCC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
IRIX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ICCC nor IRIX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.